Business
Coloplast A/S - Interim Financial Report, 9M 2024/25
Coloplast A/S - Interim Financial Report, 9M 2024/25 2024/25 Interim financial results, 9M 2024/25 1 October 2024 - 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin1 of 28% in Q3. Reported revenue in DKK grew 1% with negative impact from currencies and the Skin Care divestment. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 4% and Interventional Urology 4%.Growth in Ostomy Care was driven by br
About this update from Coloplast A/s Class B
Coloplast A/S - Interim Financial Report, 9M 2024/25 2024/25 Interim financial results, 9M 2024/25 1 October 2024 - 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin 1 of 28% in Q3. Reported revenue in DKK grew 1% with negative impact from currencies and the Skin Care divestment. 9M 2024/25 organic growth of 7% and EBIT margin 1 of 27%. Reported revenue in DKK grew 4% to DKK 20,914 million. FY 2024/25 guidance is unchanged with organic growth of around 7% and an EBIT margin before special items of 27-28%. "We deliver a third quarter as expected with 7% organic growth and an EBIT margin of 28%, maintaining our financial guidance for 2024/25. Our Q3 performance was driven by broad-based growth across our chronic care businesses, offsetting the challenges in China. I’m pleased to see the global Coloplast organisation continuing to deliver on our priorities and moving the business forward. The search for Coloplast’s new CEO remains on track. I look forward to presenting our 2030 strategy at our Capital Markets Day on 2 September alongside the new Executive Leadership Team, announced today,” says interim CEO Lars Rasmussen. For further information, please contact Investors and analysts Anders Lonning-Skovgaard Executive Vice President, CFO Tel. +45 4911 1111 Aleksandra Dimovska Vice President, Investor Relations Tel. +45 4911 1800 / +45 4911 2458 Email: [email protected] Kristine Husted Munk Senior Manager, Investor Relations Tel. +45 4911 1800 / +45 4911 3266 Email: [email protected] Simone Dyrby Helvind Senior Manager, Investor Relations Tel. +45 4911 1800 / +45 4911 2981 Email: [email protected] Press and media Peter Mønster Sr. Media Relations Manager Tel. +45 4911 2623 Email: [email protected] Address Coloplast A/S Holtedam 1 DK-3050 Humlebaek Denmark Company reg. (CVR) no. 69749917 Website www.coloplast.com This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail. Coloplast was founded on passion, ambition, and commitment. We were born from a nurse’s wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over decades, we have helped millions of people to live a more independent life and we continue to do so through innovative products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound Care, Interventional Urology and Voice and Respiratory Care. The Coloplast logo is a registered trademark of Coloplast A/S. © 2025-08. All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark. Attachment
View stock analysis, news, and events for Coloplast A/s Class B